Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial—Comparison of the efficacy of KRAS status.
Michio Nakamura
No relevant relationships to disclose
Satoshi Yuki
No relevant relationships to disclose
Masayoshi Dazai
No relevant relationships to disclose
Yoshimitsu Kobayashi
No relevant relationships to disclose
Takashi Kato
No relevant relationships to disclose
Hirohito Naruse
No relevant relationships to disclose
Mineo Kudo
No relevant relationships to disclose
Nobuaki Akakura
No relevant relationships to disclose
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha